The Analysis of Thrombocytosis, Leukocytosis, Combination of Thrombocytosis and Leukocytosis to The Result of RECIST 1.1, Progression Free Survival, Stadium of Non Small Cell Lung Cancer Patients who Received Chemotherapy
DOI:
https://doi.org/10.11594/jk-risk.05.1.2Keywords:
KPKBSK, RECIST, PFS, Trombocytosis, leucositosisAbstract
Background: Lung cancer is the most common malignancies that lead to highest mortality and morbidity. Advanced lung cancer is treated with chemotherapy and the evaluation is using RECIST. Thrombocytosis and or leukocytosis in lung cancer, theoritically stand with bad condition.The aim of this study is to analyse whether thrombocytosis and or leukocytosis can be a prognostic factor compare to the result of RECIST,Progression Free Survival and the stadium of lung cancer.
Method: This study uses retrospective analytic cross-sectional design.Data were taken from medical record at Saiful Anwar Hospital,2018-2021,processed with Chi square,Mann-Whitney, and Fisher Exact test.
Result:The result of Chi square Thrombocytosis and Leukocytosis to the first result of RECIST are ᵡ²(1) =59,659; p=0,000 and ᵡ²(1) = 5,707:p=0,017.To the median PFS 5,66 months the test are ᵡ²(1)=51,776:p=0,000; ᵡ²(1)=4,259:p=0,039.To the state of progression, the test are ᵡ² (1)=15,171:p=0,000; ᵡ²(1)=2,226:p=0,329.To stadium, Mann-Whitney test are:1145,00;Z= -1,026:p=0,305 and 1040,500;Z= -1,393:p=0,164.
Conclusion: There is statistically significance between thrombocytosis or leukocytosis to the first result of RECIST,median PFS 5,66 months.No significance to the stadium of lung cancer.Thrombocytosis and or leukocytosis can be a prognostic factor for result of chemoteraphy.
Downloads
References
Globocan. Indonesia [Internet]. 2020 [cited 2022 Jul 18]. p. 1–2. Available from: https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf
Ruszel K, Piecewicz-Szczęsna H. Immunother-apy in the treatment of non-small cell lung cancer (NSCLC)-analysis of epidemiology and cure-review. Journal of Education, Health and Sport. 2020;10(8):204–13.
Kloecker G, Arnold SM, Fraig MM, Perez CA. Lung cancer : standards of care. 2021. 492 p.
American Cancer Society. About Lung Cancer [Internet]. 2020 [cited 2022 Jul 18]. p. 1–15. Available from: https://www.cancer.org/content/dam/CRC/PDF/Public/8703.00.pdf
Stahel RA, Peters S, Garassino M, Ghielmini M. Thoracic Tumours: Essentials for Clinician, 2nd edition [Internet]. 2014. 1–131 p. Available from: www.esmo.orgwww.esmo.orgESMOPressTHORACICTUMOURS
O’Brien M (Oncologist), Besse B, Awad MM. Non-Small-Cell Lung Cancer. 2nd Editio. Ox-ford: Karger; 2022. 1–146 p.
Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD. Revised RECIST guideline version 1.1: what oncologists want to know and what radiologists need to know. American Journal of Roentgenology. 2010;195(2):281–9.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New re-sponse evaluation criteria in solid tumours: re-vised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
Zheng M. Classification and Pathology of Lung Cancer. Surg Oncol Clin N Am [Internet]. 2016;25(3):447–68. Available from: http://dx.doi.org/10.1016/j.soc.2016.02.003
Schwartz LH, Litière S, De Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1—Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132–7.
Tas D. Paraneoplastic Syndromes in Lung Can-cer. In: Lung Cancer - Strategies for Diagnosis and Treatment. InTech; 2018.
Suega K. Paraneoplastic Syndromes. Penyakit Dalam. 2011;12(1):61–75.
Boddu P, Villlines D, Aklilu M. Paraneoplastic leukocytosis and thrombocytosis as prognostic biomarkers in non-small cell lung cancer. Chi-nese Journal of Lung Cancer. 2016;19(11):725–30.
Kanaji N, Watanabe N, Kita N, Bandoh S, Tadokoro A, Ishii T, et al. Paraneoplastic syn-dromes associated with lung cancer. Vol. 5, World Journal of Clinical Oncology. Baishideng Publishing Group Co., Limited; 2014. p. 197–223.
Liu K, Jiang G, Fang N, Cai L, Du W, Jia J. Plate-let/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer. Journal of International Medical Research. 2020;48(12).
Santoso H, Chalidyanto D, Laksono AD. The Prevalence of Cancer in Indonesia: An Ecologi-cal Analysis. Indian Journal of Forensic Medi-cine & Toxicology. 2021;15(3):3170–6.
Zheng M. Classification and pathology of lung cancer. Surgical Oncology Clinics [Internet]. 2016 [cited 2024 Dec 29];25(3):447–68. Available from: DOI:10.1016/j.SOC.2016.02.003
Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück HJ, et al. Evalua-tion of tumor response, disease control, pro-gression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. Journal of Clinical Oncology [In-ternet]. 2008 [cited 2024 Dec 29];26(12):1987–92. Available from: DOI:10.1200/JCO.2007.10.8407
Dancey JE, Dodd LE, Ford R, Kaplan R, Mooney M, Rubinstein L, et al. Recommendations for the assessment of progression in randomised cancer treatment trials. Eur J Cancer [Inter-net]. 2009 [cited 2024 Dec 29];45(2):281–9. Available from: DOI: 10.1016/j.ejca.2008.10.042
Cleeland CS, Sloan JA, Cella D, Chen C, Dueck AC, Janjan NA, et al. CPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force: Recom-mendations for including multiple symptoms as endpoints in cancer clinical trials: a report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force. Cancer [Internet]. 2013 [cited 2024 Dec 29];119(2):411–20. Available from: DOI:10.1002/cncr.27744
Gutman SI, Piper M, Grant MD, Basch E, Oli-ansky DM, Aronson N. Progression-free sur-vival: what does it mean for psychological well-being or quality of life? 2013;
Freidlin B, Korn EL, Hunsberger S, Gray R, Saxman S, Zujewski JA. Proposal for the use of progression-free survival in unblinded ran-domized trials. Journal of Clinical Oncology [In-ternet]. 2007 [cited 2024 Dec 29];25(15):2122–6. Available from: DOI:10.1200/JCO.2006.09.6198
Panageas KS, Ben-Porat L, Dickler MN, Chap-man PB, Schrag D. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst [Internet]. 2007 [cited 2024 Dec 29];99(6):428–32. Available from: DOI:10.1093/jnci/djk091
Kaneda T, Yoshioka H, Tamiya M, Tamiya A, Hata A, Okada A, et al. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. BMC Cancer [Internet]. 2018 [cited 2024 Dec 29];18:1–8. Available from: DOI:10.186/s12885-017-3952-7
Zhou F, Zhou CC. Targeted therapies for pa-tients with advanced NSCLC harboring wild-type EGFR: whats new and whats enough. Cancer Commun [Internet]. 2015 [cited 2024 Dec 29];34. Available from: DOI:10.1186/s40880-015-0036-4
Davidov D. Thrombocytosis as prognostic fac-tor for survival in patients with advanced non small cell lung cancer treated with first-line chemotherapy. Journal of IMAB–Annual Pro-ceeding Scientific Papers [Internet]. 2014 [cit-ed 2024 Dec 29];20(6):560–4. Available from: DOI:10.5272/jimab.2014206.560
Kim KH, Park TY, Lee JY, Lee SM, Yim JJ, Yoo CG, et al. Prognostic significance of initial plate-let counts and fibrinogen level in advanced non-small cell lung cancer. J Korean Med Sci [Internet]. 2014 [cited 2024 Dec 29];29(4):507–11. Available from: DOI:https://doi.org/10.3346/jkms.2014.29.4.507
Honn K V, Tang DG, Chen YQ. Platelets and cancer metastasis: more than an epiphenome-non. In: Seminars in Thrombosis and Hemo-stasis [Internet]. Copyright© 1992 by Thieme Medical Publishers, Inc.; 1992 [cited 2024 Dec 29]. p. 392–415. Available from: DOI:10.1055/s-2007-1002578
Kim KH, Park TY, Lee JY, Lee SM, Yim JJ, Yoo CG, et al. Prognostic significance of initial plate-let counts and fibrinogen level in advanced non-small cell lung cancer. J Korean Med Sci. 2014;29(4):507–11.
Abukhiran IA, Jasser J, Syrbu S. Paraneoplastic leukemoid reactions induced by cytokine-secreting tumours. J Clin Pathol [Internet]. 2020 [cited 2025 Jan 20];73(6):310–3. Avail-able from: https://doi.org/10.1136/jclinpath-2019-206340
Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebi-hara Y, Ohyashiki K. Tumor‐related leukocyto-sis is linked with poor prognosis in patients with lung carcinoma. Cancer [Internet]. 2001 [cited 2024 Dec 29];92(9):2399–405. Availa-ble from: https://doi.org/10.1002/1097-0142(20011101)92::AID-CNCR1588>3.0.CO;2-W
Boddu P, Villlines D, Aklilu M. Paraneoplastic leukocytosis and thrombocytosis as prognostic biomarkers in non-small cell lung cancer. Chi-nese Journal of Lung Cancer [Internet]. 2016 [cited 2024 Dec 29];19(11):725. Available from: DOI:10.3779/j.issn.1009-3419.2016.11.02
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Jurnal Klinik dan Riset Kesehatan
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges and earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
